TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00131053
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00131053
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00131053
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00238108
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
Study: NCT00238108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04341428
Drug: DWP14012 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
Study: NCT04341428
Drug: DWP14012 20 mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
Study: NCT00835211
Drug: DDAVP® 0.2 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 0.2 mg, single-dose fasting
Study: NCT03219320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo capsules.
Study: NCT02807675
Drug: CVT-301, LIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
Study: NCT03879759
Drug: NAC 2400mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400mg/day 2 x 600mg b.d
Study: NCT03879759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 matched placebo tablets/day
Study: NCT01110642
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical lovastatin applied to red, rashy areas two times daily for 12 months
Study: NCT03815318
Drug: Recombinant Human Coagulation FVIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
Study: NCT03425253
Drug: BELKYRA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: BELKYRA® was injected into preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart).
Study: NCT04357223
Drug: extract from Angelica archangelica leaf
Normalized name: Angelica archangelica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily
Study: NCT04357223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01590758
Drug: Topical placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of treatment
Study: NCT00178113
Drug: - Certagen (multivitamins with minerals)
Normalized name: Betagen brand of Betamethasone and Gentamicin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004005
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004005
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00750152
Drug: NAFT-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream application up to 4 weeks
Study: NCT00750152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream applied for up to 4 weeks
Study: NCT02238184
Drug: Atrovent®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02238184
Drug: Ventilat®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00602927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
Study: NCT04029766
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00511329
Drug: somatropin [rDNA origin] for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
Study: NCT03229694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered orally at two hour before surgery and six hours after surgery.
Study: NCT04267900
Drug: 99mTc-HPArk2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
Study: NCT02087007
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
Study: NCT02184052
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg or 15 mg
Study: NCT02215018
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02215018
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00095147
Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
Study: NCT00095147
Drug: Placebo (PLA) + MTX, DB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
Study: NCT00095147
Drug: PLA + MTX switched to ABA+ MTX, DB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
Study: NCT00095147
Drug: ABA, open-label (OL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
Study: NCT04097951
Drug: Combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast and Bepotastine Combination
Study: NCT00181597
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Taken orally with trilostane.
Study: NCT00726401
Drug: COLD-fX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg BID for 4 weeks
Study: NCT00726401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg BID for 4 weeks
Study: NCT01256086
Drug: Formatris 24µg
Normalized name: penicillin G 24 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
Study: NCT01256086
Drug: Foradil P 24µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
Study: NCT02777320
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
Study: NCT00509665
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
Study: NCT01256086
Drug: Foradil P 12µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
Study: NCT02774902
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin tablets
Study: NCT01226823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
Study: NCT03927378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
Study: NCT04341727
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antibiotic
Study: NCT00381667
Drug: GW642444M
Approvals — FDA: no, EMA: no, PMDA: no
Description: M salt
Study: NCT00381667
Drug: GW642444H
Approvals — FDA: no, EMA: no, PMDA: no
Description: H salt
Study: NCT02449343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o. qd
Study: NCT03211052
Drug: TAK-700 and LHRH agonist
Normalized name: Somatropin and somatropin agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
Study: NCT03272568
Drug: Recombinant FVIII Fc fusion product Eloctate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
Study: NCT02121613
Drug: Permixon® 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration - 160 mg twice daily.
Study: NCT02121613
Drug: Placebo matching Permixon® 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration - twice daily.
Study: NCT01338298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole.
Study: NCT02024789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally twice daily, 26 weeks
Study: NCT02024789
Drug: RG1662
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
Study: NCT02024789
Drug: RG1662
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
Study: NCT03745885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
Study: NCT00299611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
Study: NCT01301898
Drug: GC1111_0.5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01301898
Drug: GC1111_1.0mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01301898
Drug: Elaprase_0.5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03697889
Drug: Naproxen sodium (test product)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
Study: NCT03697889
Drug: Naproxen sodium (reference product)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
Study: NCT00062803
Drug: SR34006
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00062803
Drug: (LMW)heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00062803
Drug: Acenocoumarol VKA
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01252225
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
Study: NCT00285389
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01451437
Drug: MK-8242
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
Study: NCT03603678
Drug: BAY2253651
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally
Study: NCT03603678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo dosing
Study: NCT01826201
Drug: MOL4239
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
Study: NCT01826201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
Study: NCT00622752
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X placebo tablets to match EVT 302 5 mg
Study: NCT03056456
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT01071018
Drug: MK2206 once weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
Study: NCT00027989
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00975897
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00975897
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03048383
Drug: OnabotulinumtoxinA Injectable Product
Normalized name: onabotulinumtoxinA Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to treat facial synkinesis
Study: NCT03048383
Drug: AbobotulinumtoxinA Injectable Product
Normalized name: abobotulinumtoxinA Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to treat facial synkinesis
Study: NCT03048383
Drug: Incobotulinumtoxin A Injectable Product
Normalized name: incobotulinumtoxinA Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to treat facial synkinesis
Study: NCT00609531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill once a day for twelve weeks
Study: NCT01596062
Drug: Simulect®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
Study: NCT01596062
Drug: Neoral®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
Study: NCT01596062
Drug: Certican®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
Study: NCT01596062
Drug: Myfortic®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
Study: NCT02632448
Drug: LY2880070
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT01596062
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
Study: NCT02611596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 24 weeks
Study: NCT00943072
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sham intravitreal injection out to Week 24 Primary Endpoint
Study: NCT00526916
Drug: [C-11]PBR28
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04682119
Drug: LY3526318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04682119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02405442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match andecaliximab administered via SC injection
Study: NCT03241030
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
Study: NCT03241030
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
Study: NCT00444678
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2500 mg, po bid x 7 days every two weeks
Study: NCT00504946
Drug: prednisone, lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose
Study: NCT00504946
Drug: prednisone, colecalciferol, lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose
Study: NCT00504946
Drug: lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose
Study: NCT00504946
Drug: lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
Study: NCT02713607
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given doxycycline to acne subjects
Study: NCT01816334
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00118209
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT00118209
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV or CIVI
Study: NCT04664764
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal insulin comparison
Study: NCT02180659
Drug: placebo implants
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02180659
Drug: sublingual placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01872832
Drug: RDEA3170 and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00640224
Drug: drospirenone/ethinyl estradiol
Normalized name: DROSPIRENONE/ETHINYL ESTRADIOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab (3mg/30mcg) daily for 6 months
Study: NCT02535156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose Placebo
Study: NCT01254162
Drug: MTC896 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% w/w gel applied daily for 28 days to the forehead
Study: NCT01667419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
Study: NCT01343381
Drug: Hepalean Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 units per kilogram bolus prior to initiation of CPB
Study: NCT01343381
Drug: PPC Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 unit per kilogram bolus prior to initiation of CPB
Study: NCT00157482
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03632408
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01839604
Drug: AZD9150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion over 3 hours.